Soluble Fibre Enriched CHO Food Study
Launched by UNITY HEALTH TORONTO · Jul 9, 2013
Trial Information
Current as of June 24, 2025
Unknown status
Keywords
ClinConnect Summary
Literature to date points to beneficial glycemic effects from consumption of soluble fibre; however, whole grain products consumption is below recommendations possibly due to the presence of unappealing characteristic organoleptic properties. White, refined products are still the choice of the general public. As such, we propose to investigate the feasibility of increasing health benefits of commonly consumed white, refined carbohydrate products by incorporating a soluble fibre blend.
This research is important to determine the feasibility of developing fibre enriched carbohydrate foods th...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Normotensive (SBP\<140mmHg, DBP \<90mmHg)
- • BMI 18.5 - 25 kg/m2
- • Post-menopausal or not pregnant women
- Exclusion Criteria:
- • Allergy or sensitivity to test meals
- • Swallowing difficulties
- • Chronic use of medications or fibre
- • GI conditions affecting stomach pH
- • Must not be enrolled in another study
- • History of liver or kidney disease, diabetes, hypertension, stroke or myocardial infarctions, thyroid disease, celiac /gastrointestinal disease, HIV positive or AIDS
About Unity Health Toronto
Unity Health Toronto is a leading healthcare organization dedicated to providing exceptional patient care, advancing medical research, and fostering education in the field of health sciences. Comprising St. Michael's Hospital, St. Joseph's Health Centre, and Providence Healthcare, Unity Health integrates a diverse range of clinical services and innovative research initiatives. The organization is committed to improving health outcomes through collaborative partnerships and community engagement, while upholding the highest standards of ethics and integrity in its clinical trials and research endeavors. By focusing on patient-centered approaches, Unity Health Toronto aims to drive advancements in healthcare and contribute to the well-being of the communities it serves.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Patients applied
Trial Officials
Vladimir Vuksan, PhD
Principal Investigator
St. Michael's & University of Toronto
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials